ClearBridge Investments’s AnaptysBio ANAB Stock Holding History

ClearBridge Investments’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-116	Closed	-$4K	–	1093
2019 Q3	$4K	Hold	116	–	–	﹤0.01%	1048
2019 Q2	$7K	Hold	116	–	–	﹤0.01%	1009
2019 Q1	$8K	Hold	116	–	–	﹤0.01%	1003
2018 Q4	$7K	Hold	116	–	–	﹤0.01%	1040
2018 Q3	$12K	Hold	116	–	–	﹤0.01%	1042
2018 Q2	$8K	Sell	116 -70	-38%	-$5.87K	﹤0.01%	1030
2018 Q1	$19K	Buy	+186	New	+$21K	﹤0.01%	981

Other funds holding ANAB

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ClearBridge Investments's ANAB Position: Q4 2019 in Review

ClearBridge Investments sold out of AnaptysBio (ANAB) in Q4 2019, closing a stake of 116 shares — an estimated $4K sold.

ClearBridge Investments first reported a position in ANAB in Q1 2018 and held it in 7 quarters. The position peaked at $19K in Q1 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

ClearBridge Investments reported no remaining AnaptysBio position as of Q4 2019 after selling out during the quarter.
ClearBridge Investments sold 116 AnaptysBio shares in Q4 2019, an estimated $4K.
ClearBridge Investments first reported a position in AnaptysBio in Q1 2018 and held it in 7 quarters.
ClearBridge Investments's AnaptysBio position peaked at $19K in Q1 2018.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on ClearBridge Investments's 13F filing for Q4 2019, filed 14 Feb 2020.